Please assess the completion status of the following clinical trial:

Trial Title: Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Signed written informed consent before any trial-related processes;~2. Age ≥ 18 years and \<75 years male or females;~3. Has a histologically or cytologically confirmed stage IIIB/IIIC (American Joint Committee on Cancer \[AJCC\] 8th edition) NSCLC that is unresectable and not fit for radical concurrent chemoradiotherapy, or metastatic / recurrent non-squamous NSCLC;~4. Patients with EGFR mutation confirmed by tumor histology or cytology or hematology prior to EGFR-TKI treatment~5. EGFR-TKI resistance, confirmed by RECIST 1.1~6. The investigator confirms at least one measurable lesion according to RECIST 1.1. A measurable lesion located in the field of previous radiation therapy or after local treatment may be selected as a target lesion if progression is confirmed; The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1;~Exclusion criteria:~1. Squamous cell \> 10%. If small cell types are present, the subject is not eligible for inclusion.;~2. Has previously received systemic anti-tumor treatment other than EGFR-TKI for or advanced non-squamous NSCLC (including cytotoxic chemotherapy for radiotherapy, do not include other systemic treatment for other cured tumors);~3. Has previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or any other stimulatory or inhibitory agents of T cell receptors (eg CTLA-4, OX-40, CD137);~4. Has received EGFR-TKI treatment within 2 weeks;~5. Diagnosed of immunodeficiency or has received systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drugs.~6. History of pneumonitis requiring steroid therapy or the presence of interstitial lung disease within 1 year prior to the first dose of study drugs;~7. Symptomatic central nervous system metastases (CNS) metastasis and/or cancerous meningitis.~   Hemoptysis within 3 months,~8. Full-dose oral or parenteral anticoagulant or thrombolytic agent for 10 consecutive days within 2 weeks. prophylactic use of anticoagulants is allowed;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sintilimab +IBI305+Pemetrexed+Cisplatin (Type: EXPERIMENTAL): Drug: Sintilimab 200mg IV Q3W Other Name: IBI308~Drug: IBI305 15mg/kg IV Q3W~Drug: Pemetrexed 500mg/m2 IV Q3W~Drug: Cisplatin 75mg/m2 IV Q3W
- Sintilimab +Placebo2+Pemetrexed+Cisplatin (Type: EXPERIMENTAL): Drug: Sintilimab 200mg IV Q3W Other Name: IBI308~Drug: Pemetrexed 500mg/m2 IV Q3W~Drug: Cisplatin 75mg/m2 IV Q3W~Drug: Placebo2 Placebo2 IV Q3W
- Placebo1+Placebo2+Pemetrexed+Cisplatin (Type: ACTIVE_COMPARATOR): Drug: Pemetrexed 500mg/m2 IV Q3W~Drug: Cisplatin 75mg/m2 IV Q3W~Drug: Placebo1 Placebo1 IV Q3W~Drug: Placebo2 Placebo2 IV Q3W

Based on this trial design, predict the completion outcome and termination type (if applicable).